[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100391347":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":327,"collaborators":27,"id":329,"slug":330,"hasResults":331,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":27,"eligibilityCriteria":335,"healthyVolunteers":331,"sex":336,"minAge":337,"maxAge":338,"enrollmentInfo":339,"targetDuration":27,"studyType":342,"phases":343,"briefSummary":345,"conditions":346,"keywords":27,"overallStatus":60,"whyStopped":27,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":357},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Doravirine as a single entity plus 2 NRTIs or Doravirine as a FDC with 3TC and TDF","EXPERIMENTAL","Participants receive doravirine (DOR) at 7.2 mg to 100 mg, based on weight, PLUS 2 nucleoside\u002Fnucleotide analog reverse transcriptase inhibitors (NRTIs), based on local label, for 96 weeks, OR a fixed-dose combination (FDC) of doravirine\u002Flamivudine\u002Ftenofovir disoproxil fumarate (DOR\u002F3TC\u002FTDF), based on weight, for 96 weeks.",[13,14,15],"Drug: Doravirine","Drug: 2 NRTIs","Drug: DOR\u002F3TC\u002FTDF",[17,24,28],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Doravirine","Administered orally",[9],[23],"MK-1439",{"type":18,"name":25,"description":20,"armGroupLabels":26,"otherNames":27},"2 NRTIs",[9],null,{"type":18,"name":29,"description":20,"armGroupLabels":30,"otherNames":31},"DOR\u002F3TC\u002FTDF",[9],[32],"MK-1439A",[34],{"name":35,"affiliation":5,"role":36},"Medical Director","STUDY_DIRECTOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":27,"email":42},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[44,58,73,88,101,114,126,135,145,160,170,180,189,202,214,227,236,242,255,268,280,289,303,315],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":27},"University of Colorado at Denver ( Site 0108)","COMPLETED","Aurora","Colorado","80045","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-104.83192,39.72943,{"lat":56,"lon":55},{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":50,"countryCode":51,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Emory Children's Center ( Site 0103)","RECRUITING","Atlanta","Georgia","30322",{"type":53,"coordinates":65},[66,67],-84.38798,33.749,{"lat":67,"lon":66},[70],{"name":71,"role":40,"phone":72,"phoneExt":27,"email":27},"Study Coordinator","404-727-5642",{"facility":74,"status":60,"city":75,"state":76,"zip":77,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Clinica Somer ( Site 1003)","Rionegro","Antioquia","054040","Colombia","CO",{"type":53,"coordinates":81},[82,83],-75.37371,6.15515,{"lat":83,"lon":82},[86],{"name":71,"role":40,"phone":87,"phoneExt":27,"email":27},"+573235903405",{"facility":89,"status":60,"city":90,"state":91,"zip":92,"country":78,"countryCode":79,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Ciensalud Ips S A S ( Site 1001)","Barranquilla","Atlántico","080020",{"type":53,"coordinates":94},[95,96],-74.78132,10.96854,{"lat":96,"lon":95},[99],{"name":71,"role":40,"phone":100,"phoneExt":27,"email":27},"573183894721",{"facility":102,"status":60,"city":103,"state":104,"zip":105,"country":78,"countryCode":79,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"CEIP - Centro de Estudios en Infectología Pediátrica ( Site 1002)","Cali","Valle del Cauca Department","760042",{"type":53,"coordinates":107},[108,109],-76.5199,3.43054,{"lat":109,"lon":108},[112],{"name":71,"role":40,"phone":113,"phoneExt":27,"email":27},"573155798444",{"facility":115,"status":46,"city":116,"state":117,"zip":118,"country":119,"countryCode":120,"cosmosGeoPoint":121,"geoPoint":125,"contacts":27},"Instituto Nacional de Pediatria ( Site 0701)","Coyoacán","Mexico City","04530","Mexico","MX",{"type":53,"coordinates":122},[123,124],-99.16174,19.3467,{"lat":124,"lon":123},{"facility":127,"status":128,"city":117,"state":117,"zip":129,"country":119,"countryCode":120,"cosmosGeoPoint":130,"geoPoint":134,"contacts":27},"Hospital Infantil de Mexico Federico Gomez ( Site 0702)","ACTIVE_NOT_RECRUITING","06720",{"type":53,"coordinates":131},[132,133],-99.12766,19.42847,{"lat":133,"lon":132},{"facility":136,"status":46,"city":137,"state":138,"zip":139,"country":119,"countryCode":120,"cosmosGeoPoint":140,"geoPoint":144,"contacts":27},"Unidad de Atencion Medica e Investigacion en Salud S.C. ( Site 0700)","Mérida","Yucatán","97000",{"type":53,"coordinates":141},[142,143],-89.62318,20.967,{"lat":143,"lon":142},{"facility":146,"status":60,"city":147,"state":148,"zip":149,"country":150,"countryCode":151,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"Kuzbasskiy Center for the Prevention and Control of AIDS ( Site 0506)","Kemerovo","Kemerovo Oblast","650056","Russia","RU",{"type":53,"coordinates":153},[154,155],86.10435,55.35417,{"lat":155,"lon":154},[158],{"name":71,"role":40,"phone":159,"phoneExt":27,"email":27},"79069261368",{"facility":161,"status":46,"city":162,"state":163,"zip":164,"country":150,"countryCode":151,"cosmosGeoPoint":165,"geoPoint":169,"contacts":27},"Clinical Centre for Prevention and Control of AIDS ( Site 0504)","Krasnodar","Krasnodarskiy Kray","350015",{"type":53,"coordinates":166},[167,168],38.98178,45.04534,{"lat":168,"lon":167},{"facility":171,"status":46,"city":172,"state":173,"zip":174,"country":150,"countryCode":151,"cosmosGeoPoint":175,"geoPoint":179,"contacts":27},"Krasnoyarsk Regional Center for Prevention and Control of AIDS ( Site 0507)","Krasnoyarsk","Krasnoyarsk Krai","660049",{"type":53,"coordinates":176},[177,178],92.93136,56.03742,{"lat":178,"lon":177},{"facility":181,"status":46,"city":182,"state":182,"zip":183,"country":150,"countryCode":151,"cosmosGeoPoint":184,"geoPoint":188,"contacts":27},"Infectious Clinical Hospital #2 ( Site 0501)","Moscow","105275",{"type":53,"coordinates":185},[186,187],37.61781,55.75204,{"lat":187,"lon":186},{"facility":190,"status":60,"city":191,"state":192,"zip":193,"country":150,"countryCode":151,"cosmosGeoPoint":194,"geoPoint":198,"contacts":199},"FGU Republican Clinical Infectious Hospital of Roszdrav ( Site 0500)","Saint Petersburg","Sankt-Peterburg","196645",{"type":53,"coordinates":195},[196,197],30.31413,59.93863,{"lat":197,"lon":196},[200],{"name":71,"role":40,"phone":201,"phoneExt":27,"email":27},"+78124649329",{"facility":203,"status":46,"city":204,"state":205,"zip":206,"country":207,"countryCode":208,"cosmosGeoPoint":209,"geoPoint":213,"contacts":27},"FARMOVS PTY LTD ( Site 0601)","Bloemfontein","Free State","9301","South Africa","ZA",{"type":53,"coordinates":210},[211,212],26.214,-29.12107,{"lat":212,"lon":211},{"facility":215,"status":60,"city":216,"state":217,"zip":218,"country":207,"countryCode":208,"cosmosGeoPoint":219,"geoPoint":223,"contacts":224},"Perinatal HIV Research Unit ( Site 0602)","Johannesburg","Gauteng","1864",{"type":53,"coordinates":220},[221,222],28.04363,-26.20227,{"lat":222,"lon":221},[225],{"name":71,"role":40,"phone":226,"phoneExt":27,"email":27},"+2711 989 9700",{"facility":228,"status":60,"city":216,"state":217,"zip":229,"country":207,"countryCode":208,"cosmosGeoPoint":230,"geoPoint":232,"contacts":233},"Wits Reproductive Health and HIV Institute (WRHI) ( Site 0603)","2001",{"type":53,"coordinates":231},[221,222],{"lat":222,"lon":221},[234],{"name":71,"role":40,"phone":235,"phoneExt":27,"email":27},"+27 11 358 5300",{"facility":237,"status":46,"city":216,"state":217,"zip":238,"country":207,"countryCode":208,"cosmosGeoPoint":239,"geoPoint":241,"contacts":27},"Empilweni Services and Research Unit ( Site 0604)","2093",{"type":53,"coordinates":240},[221,222],{"lat":222,"lon":221},{"facility":243,"status":60,"city":244,"state":245,"zip":246,"country":207,"countryCode":208,"cosmosGeoPoint":247,"geoPoint":251,"contacts":252},"King Edward Hospital ( Site 0600)","Durban","KwaZulu-Natal","4001",{"type":53,"coordinates":248},[249,250],31.0292,-29.8579,{"lat":250,"lon":249},[253],{"name":71,"role":40,"phone":254,"phoneExt":27,"email":27},"+27312611093",{"facility":256,"status":60,"city":257,"state":258,"zip":259,"country":207,"countryCode":208,"cosmosGeoPoint":260,"geoPoint":264,"contacts":265},"Family Clinic Research With UBUNTU ( Site 0605)","Cape Town","Western Cape","7505",{"type":53,"coordinates":261},[262,263],18.42322,-33.92584,{"lat":263,"lon":262},[266],{"name":71,"role":40,"phone":267,"phoneExt":27,"email":27},"+27219384153",{"facility":269,"status":60,"city":270,"state":258,"zip":271,"country":207,"countryCode":208,"cosmosGeoPoint":272,"geoPoint":276,"contacts":277},"Be Part Yoluntu Centre ( Site 0606)","Paarl","7626",{"type":53,"coordinates":273},[274,275],18.97523,-33.73378,{"lat":275,"lon":274},[278],{"name":71,"role":40,"phone":279,"phoneExt":27,"email":27},"+2782 660 5795",{"facility":281,"status":46,"city":282,"state":258,"zip":283,"country":207,"countryCode":208,"cosmosGeoPoint":284,"geoPoint":288,"contacts":27},"Tsitsikamma Clinical Research Initiative (TCRI) ( Site 0607)","Plettenberg Bay","6600",{"type":53,"coordinates":285},[286,287],23.3716,-34.05274,{"lat":287,"lon":286},{"facility":290,"status":60,"city":291,"state":291,"zip":292,"country":293,"countryCode":294,"cosmosGeoPoint":295,"geoPoint":299,"contacts":300},"Siriraj Hospital ( Site 0901)","Bangkok","10700","Thailand","TH",{"type":53,"coordinates":296},[297,298],100.50144,13.75398,{"lat":298,"lon":297},[301],{"name":71,"role":40,"phone":302,"phoneExt":27,"email":27},"+6624180545",{"facility":304,"status":60,"city":305,"state":27,"zip":306,"country":293,"countryCode":294,"cosmosGeoPoint":307,"geoPoint":311,"contacts":312},"Research Institute for Health Sciences ( Site 0902)","Chiang Mai","50200",{"type":53,"coordinates":308},[309,310],98.98468,18.79038,{"lat":310,"lon":309},[313],{"name":71,"role":40,"phone":314,"phoneExt":27,"email":27},"+6653936148",{"facility":316,"status":60,"city":317,"state":27,"zip":318,"country":293,"countryCode":294,"cosmosGeoPoint":319,"geoPoint":323,"contacts":324},"Faculty of Medicine - Khon Kaen University ( Site 0903)","Khon Kaen","40002",{"type":53,"coordinates":320},[321,322],102.833,16.44671,{"lat":322,"lon":321},[325],{"name":71,"role":40,"phone":326,"phoneExt":27,"email":27},"+66897112236",{"type":328,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100391347","phase-2-doravirine-dor-in-human-immunodeficiency-virus-hiv-infected-children-aged-4-weeks-to-12-years-and-45-kg-mk-1439-066-100391347",false,"NCT04375800","Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to \u003C12 Years and \u003C45 kg (MK-1439-066)","A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine and Doravirine\u002FLamivudine\u002FTenofovir Disoproxil Fumarate in Participants With HIV-1, Who Are 4 Weeks to Less Than 12 Years of Age and Weigh Less Than 45 kg","Inclusion Criteria:\n\n* Has human immunodeficiency virus type 1 (HIV-1) infection confirmed at screening\n* Has appropriate treatment history defined as treatment-naïve (TN) or with documented virologic suppression (HIV-1 ribonucleic acid \\[RNA\\] \\\u003C50 copies\u002FmL) on stable combination antiretroviral therapy (cART) for ≥3 months\n* Body weight is \\>3 kg to \\\u003C45 kg\n* If female, is not pregnant or breastfeeding, and one of the following applies:\n* Is not a woman of childbearing potential (WOCBP)\n* Is a WOCBP using an acceptable form of contraception, or is abstinent\n* If a WOCBP must have a negative pregnancy test (urine or serum) within 24 hours of the first dose of study intervention\n\nStudy Extension Inclusion Criteria:\n\n* Has completed the Week 96 visit\n* Is considered, in the opinion of the investigator, to have derived benefit from treatment with doravirine (DOR) plus the 2 nucleoside\u002Fnucleotide analog reverse transcriptase inhibitor (NRTIs) selected by the investigator, or doravirine\u002Flamivudine\u002Ftenofovir disoproxil fumarate (DOR\u002F3TC\u002FTDF), by Week 96 of the study\n* Is considered, in the opinion of the investigator, to be a clinically appropriate candidate for additional treatment with DOR regimens (DOR plus 2 NRTIs selected by the investigator or DOR\u002F3TC\u002FTDF)\n* Understands the procedures in the study extension and has provided (or have the participant's legally acceptable representative, if applicable, provide) documented informed consent\u002Fassent to enter the study extension and continue treatment with DOR regimens (DOR plus 2 NRTIs selected by the investigator or DOR\u002F3TC\u002FTDF) until it is available locally in countries participating in the study or for up to an additional 224 weeks (whichever comes first)\n\nExclusion Criteria:\n\n* Has evidence of renal disease\n* Demonstrates evidence of liver disease\n* Has clinical or laboratory evidence of pancreatitis\n* Has any history of malignancy\n* Has presence of any active acquired immunodeficiency syndrome (AIDS)-defining opportunistic Infection\n* Has an active diagnosis of hepatitis, including hepatitis B co-infection\n* Has current active tuberculosis and\u002For is being treated with a rifampicin-containing regimen\n* Has a medical condition that precludes absorption or intake of oral pellets\u002Fgranules\n* Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound results of the study or interfere with participating for the entire duration of the study\n* Is taking or is anticipated to require systemic immunosuppressive therapy, immune modulators, or other prohibited therapy\n* Is currently participating in or has participated in an interventional clinical study with an investigational compound or device from 45 days prior to Day 1 through the treatment period\n* Has a documented or known virologic resistance to DOR\n* Has any history of viremia (HIV RNA \\>1000 copies\u002FmL) after at least 3 months on a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen","ALL","4 Weeks","11 Years",{"count":340,"type":341},84,"ESTIMATED","INTERVENTIONAL",[344],"PHASE2","This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to \\\u003C12 years and weighing \\\u003C45 kg, who are treatment-naive (TN) or have been virologically suppressed (VS) on stable combination antiretroviral therapy (cART) for ≥3 months with no history of treatment failure. The primary objectives are:\n\n* To evaluate the steady state pharmacokinetics (PK) of doravirine (DOR) \\[MK-1439\\] when given in combination with 2 nucleoside\u002Fnucleotide analog reverse transcriptase inhibitors (NRTIs) or as part of the fixed-dose combination (FDC) of DOR\u002Flamivudine (3TC)\u002Ftenofovir disproxil fumarate (TDF) in participants ≥6 to \\\u003C12 years and weighing ≥14 to \\\u003C45 kg.\n* To evaluate the safety and tolerability of DOR when given with 2 NRTIs or as part of the FDC of DOR\u002F3TC\u002FTDF, in participants ≥6 to 12 years and weighing ≥14 to \\\u003C45 kg, through Week 24.",[347],"Human Immunodeficiency Virus (HIV) Infection","2026-04-24",{"date":350,"type":351},"2026-04-28","ACTUAL",{"date":353,"type":351},"2021-02-03",{"date":355,"type":341},"2034-04-11",{"name":5,"class":6},24]